Revolutionizing Healthcare: Biofourmis Secures $100 Million in Series C Funding

Biofourmis, a pioneering global technology company based in Boston with key offices in Singapore and India, has successfully raised $100 million in its latest funding round, a testament to the growing demand for its innovative healthcare solutions. With a mission to deliver the right care to every individual, regardless of their location, Biofourmis utilizes its advanced AI-driven platform to collect and analyze more than 120 biomarkers in real-time. This groundbreaking technology allows healthcare providers to identify shifts in patients' conditions that necessitate timely, proactive interventions, ultimately transforming the way care is delivered. The newly secured funding will be strategically allocated to enhance its research and development initiatives, fortifying Biofourmis' capability to extend hospital-level services, virtual provider networks, and groundbreaking clinical trials without requiring patients to leave their homes. With partnerships rooted in trust across leading health systems, payers, and biopharma companies, Biofourmis is committed to improving patient outcomes, preventing hospitalization readmissions, and expediting drug development processes. This funding not only empowers the company to close critical gaps in care but also aligns with its overarching goal of making science smarter, healthcare simpler, and patients healthier. As Biofourmis explores new horizons in healthcare technology, its commitment to delivering connected care remains unwavering. For more insights into their innovative solutions, visit biofourmis.com and connect with them on LinkedIn, Twitter, and YouTube.